Has Lianke Mu, MD received payments from drug or device companies?

Yes. Drug and device makers reported $14,457 in general payments to Lianke Mu, MD across 826 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Lianke Mu, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Lianke Mu, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Lianke Mu, MD

Endocrinology, Diabetes & Metabolism · Gadsden, ALNPI 1700847720

Payments from drug & device makers

$14,457in general payments, 2019–2025

Across 826 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$2K
Lilly USA, LLC$2K
Novo Nordisk$1K
Sanofi-aventis U.S. LLC$1K
Dexcom, Inc.$816
Amgen$804
plus $6K from 36 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	108	$2,391
Lilly USA, LLC	132	$2,158
Novo Nordisk	96	$1,358
Sanofi-aventis U.S. LLC	57	$1,109
Dexcom, Inc.	53	$816
Amgen(2 entities)	52	$804
Abbott	46	$756
Amarin Pharma, Inc.	45	$722
Merck	41	$637
Xeris Pharmaceuticals, Inc.	29	$613
Corcept Therapeutics	25	$462
Boehringer Ingelheim	27	$437
AbbVie	18	$316
Lifescan, Inc.	17	$285
IBSA Pharma Inc.	11	$224
Esperion Therapeutics, Inc.	8	$135
Tandem Diabetes Care, Inc.	5	$133
Bayer	7	$118
Insulet Corporation	5	$111
Sanofi	1	$105
Novartis	5	$99
Medtronic(2 entities)	4	$99
Radius Health, Inc.	4	$71
Regeneron Healthcare Solutions, Inc.	4	$58
Kyowa Kirin, Inc.	2	$45
Takeda Pharmaceuticals U.S.A., Inc.	2	$41
BETA Bionics, Inc.	2	$41
Ultragenyx Pharmaceutical Inc.	2	$38
Kowa Pharmaceuticals America, Inc.	3	$36
BD	2	$29
Ascendis Pharma Endocrinology Inc	1	$25
Pfizer	2	$24
Neurocrine Biosciences, Inc.	1	$24
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$18
Zealand Pharma US, Inc.	1	$17
GSK	1	$17
Embecta Corp.	1	$17
Shire North American Group Inc	1	$16
GRT US Holding, Inc.	1	$16
Johnson & Johnson	1	$15
Boston Scientific	1	$12
Mannkind Corporation	1	$12

How this compares

$14,457 in reported general payments places this provider in the 70th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.

See all endocrinology, diabetes & metabolism providers in Alabama →

Medicare billing

Part B allowed, 2024

$80,919

Medicare patients

255

Services billed

757

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Gadsden

Dominic HomanGadsden$35K
William GarveyBirmingham$3.8M
Neil SchaffnerOpelika$642K
Fernando OvalleBirmingham$516K
Ralph TeagueBirmingham$487K
Bantwal BaligaOpelika$483K
Judson MenefeeFairhope$185K
Amy WarrinerBirmingham$182K
William DebellTuscaloosa$161K
Edison GoncalvesBirmingham$142K

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →